絞り込み

16594

広告

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).

著者 Drgona L , Gudiol C , Lanini S , Salzberger B , Ippolito G , Mikulska M
Clin Microbiol Infect.2018 Mar 20 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (207view , 0users)

Full Text Sources

Medical

The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies.
PMID: 29572070 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード